Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026GlobeNewsWire · 4 days ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 1, 2026
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's LimitationsSeeking Alpha · Sep 25, 2026
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha · Sep 10, 2026
Solid Biosciences to Participate at Upcoming Investor ConferencesGlobeNewsWire · Sep 2, 2026Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.46 | -$0.38 | Beat |
| May 12, 2026 | -$0.40 | -$0.52 | Miss |
| Mar 19, 2026 | -$0.51 | -$0.50 | Beat |
| Nov 3, 2025 | -$0.42 | -$0.48 | Miss |
| Aug 12, 2025 | -$0.51 | -$0.42 | Beat |
| May 15, 2025 | -$0.53 | -$0.59 | Miss |